Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial - Fizazi, K; Tran, N; Fein, L (The Lancet Oncology, 2019)
et al.